Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Breast Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Breast Cancer
    Study Identifies Causes of Bone Loss in Breast Cancer Survivors - (DGNews)
    TopAbstracts in Breast Cancer 11/18/2008 - (DGNews)
    Psychological Interventions Associated With Breast Cancer Survival - (DGNews)
    Aromatase Inhibitors, Androgen Deprivation Increase Risk of Bone Loss - (DGNews)
    TopAbstracts in Breast Cancer 11/11/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Breast Cancer

    Webcasts/CME archive

     Recent cases - Breast Cancer
      Presentation and Course of Brain Metastases from Breast Cancer in a Paranoid-Schizophrenic Patient: A Case Report
      Granular Cell Tumour of the Pectoral Muscle Mimicking Breast Cancer
      Primary Osteosarcoma of the Breast: Case Report
      A Case of Matrix-Producing Carcinoma of the Breast
      Metastatic Hurthle Cell Carcinoma of the Thyroid Presenting as a Breast Lump: A Case Report

      Cases archive
        




      my personal edition > breast cancer > news
      divider

        E-Mail this DGNews to a colleague

      DGNews


      Albumin-Bound Paclitaxel Approved for Metastatic Breast Cancer in China

        LOS ANGELES -- July 14, 2008 -- The China State Food and Drug Administration has approved albumin-bound paclitaxel ABI-007 (Abraxane) for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. The phase 3 clinical trials in the United States and China, on which this approval was based, demonstrated that albumin-bound paclitaxel doubled the response rate, significantly prolonged time to tumour progression, and in the US trial, significantly improved overall survival versus paclitaxel (Taxol) in the approved indication. Abraxane is a solvent-free nanoparticle including albumin that encapsulates paclitaxel. Taxol consists of the taxane in a cremophor solvent.

        Data from the pivotal US head-to-head trial demonstrated that albumin-bound paclitaxel nearly doubled the overall response rate versus paclitaxel and achieved a 25% improvement in time to tumour progression when compared with paclitaxel. Furthermore, patients receiving albumin-bound paclitaxel in the second-line setting had a significantly prolonged survival by an additional 27% compared with solvent-based paclitaxel. The tolerability with albumin-bound paclitaxel and paclitaxel was comparable, despite the 50% greater dose of paclitaxel administered as albumin-bound paclitaxel.

        A second head-to-head trial in Chinese patients with metastatic breast cancer further demonstrated the improved efficacy of albumin-bound paclitaxel compared with solvent-based paclitaxel injection. Albumin-bound paclitaxel significantly improved overall response rate versus solvent-based paclitaxel injection and achieved a 26% improvement in progression-free survival when compared to solvent-based paclitaxel injection. Both therapies had similar toxicity profiles.

        Albumin-bound paclitaxel is now approved for marketing in 35 countries.


        SOURCE: Abraxis Bioscience, Inc.




      E-Mail this DGNews to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send